Roche Holding Stock Forecast for 2023 - 2025 - 2030
Updated on 04/25/2024
Roche Holding Stock Forecast and Price Target
Roche Holding's stock is projected to advance by 22.64% from the previous closing price if it reaches the average target of CHF272.50 by the year's end, as nine reputable analysts recently projected. This potential upside is calculated on a high-end estimate of CHF420.00 and a low-end estimate of CHF210.00. If you're looking for information on Roche Holding stock, consider checking out the forecasts for comparable firms such as NasdaqGS:AMGN.
22.64% Upside
Roche Holding Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Roche Holding's Price has seen a drop from CHF283.57 to CHF0.00 – a 100.00% decrease. In the next year, analysts expect Fair Value to reach CHF294.67 – an increase of 100.00%. For the next seven years, the forecast is for Fair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| AAPL Stock Forecast | Apple | Outperform |
16
|
$169.02 | Buy/Sell | $200.65 | 18.33% |
| LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$732.20 | Buy/Sell | $636.99 | 14.38% |
| AVGO Stock Forecast | Broadcom | Outperform |
8
|
$1.26k | Buy/Sell | $1.21k | 23.33% |
| ABBV Stock Forecast | AbbVie | Outperform |
9
|
$167.80 | Buy/Sell | $178.42 | 12.63% |
| AZN Stock Forecast | AstraZeneca PLC | Outperform |
17
|
£113.52 | Buy/Sell | £165.99 | 42.55% |
Roche Holding Revenue Forecast for 2023 - 2025 - 2030
Roche Holding's Revenue has increased by 0.16% In the last three years, going from CHF60.34B to CHF60.44B. In the next year, analysts expect Revenue to reach CHF62.27B – an increase of 3.03%. For the next seven years, the forecast is for Revenue to grow by 34.25%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ABT Stock Forecast | Abbott Laboratories | Outperform |
9
|
$106.89 | Buy/Sell | $118.92 | 18.35% |
| DHR Stock Forecast | Danaher | Outperform |
10
|
$250.41 | Buy/Sell | $260.33 | 7.82% |
| GE Stock Forecast | General Electric | Outperform |
8
|
$159.19 | Buy/Sell | $144.00 | 8.99% |
.jpg)
Roche Holding Dividend per Share Forecast for 2023 - 2025 - 2030
In the last three years, Roche Holding's Dividend per Share has grown, increasing from CHF9.10 to CHF9.60 – a growth of 5.49%. The next year looks promising for Roche Holding, with analysts predicting Dividend per Share of CHF9.88 – an increase of 2.92%. Over the next seven years, experts anticipate that Roche Holding's Dividend per Share will grow at a rate of 31.46%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| AMGN Stock Forecast | Amgen | Outperform |
4
|
$273.01 | Buy/Sell | $303.65 | 16.20% |
| BMY Stock Forecast | Bristol-Myers Squibb | Hold |
2
|
$48.86 | Buy/Sell | $58.15 | 12.57% |
| BSX Stock Forecast | Boston Scientific | Outperform |
11
|
$72.91 | Buy/Sell | $70.14 | 0.12% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| GILD Stock Forecast | Gilead Sciences Inc | Outperform |
11
|
$67.08 | Buy/Sell | $87.82 | 19.26% |
| BDX Stock Forecast | Becton Dickinson and Co | Outperform |
9
|
$233.83 | Buy/Sell | $284.47 | 19.75% |
| 4568 Stock Forecast | Daiichi Sankyo Company | Buy |
4
|
¥4.73k | Buy/Sell | ¥5.24k | 22.65% |
Roche Holding EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Roche Holding's EBITDA has decreased from CHF23.90B to CHF20.92B – a 12.47% drop. Next year, analysts are expecting EBITDA to reach CHF24.25B – an increase of 15.95%. Over the next seven years, the forecast is for EBITDA to grow by 66.20%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 4519 Stock Forecast | Chugai Pharmaceutical | Outperform |
6
|
¥5.15k | Buy/Sell | ¥4.92k | 19.39% |
| MMM Stock Forecast | 3M | Hold |
10
|
$92.02 | Buy/Sell | $109.39 | 8.67% |
| DXCM Stock Forecast | DexCom Inc | Buy |
12
|
$137.87 | Buy/Sell | $125.98 | 8.80% |
Roche Holding EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Roche Holding's EBIT has decreased by 9.74%, going from CHF19.70B to CHF17.78B. For next year, analysts predict EBIT of CHF21.37B, which would mean an increase of 20.20%. Over the next seven years, experts predict that Roche Holding's EBIT will grow at a rate of 81.15%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ALC Stock Forecast | Alcon | Outperform |
8
|
CHF72.80 | Buy/Sell | CHF90.64 | 32.36% |
| A Stock Forecast | Agilent Technologies | Outperform |
10
|
$137.49 | Buy/Sell | $138.82 | 10.19% |
| CTVA Stock Forecast | Corteva | Outperform |
12
|
$54.77 | Buy/Sell | $61.72 | 16.85% |
Roche Holding EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Roche Holding's EPS has seen a drop from CHF19.16 to CHF0.00 – a 100.00% decrease. In the next year, analysts expect EPS to reach CHF19.91 – an increase of 100.00%. For the next seven years, the forecast is for EPS to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| DD Stock Forecast | DuPont de Nemours | Outperform |
17
|
$73.96 | Buy/Sell | $75.38 | 8.17% |
| BIIB Stock Forecast | Biogen | Outperform |
10
|
$201.99 | Buy/Sell | $299.62 | 44.56% |
| BAYN Stock Forecast | Bayer | Hold |
5
|
26.97€ | Buy/Sell | 45.15€ | 18.65% |
.jpg)